Precipio Continues To Sign New HemeScreen Customers Expected To Bring Total Q4 HemeScreen Revenues To An Estimated $1.2M
Portfolio Pulse from Benzinga Newsdesk
Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO) expects new customer orders to bring total Q4 HemeScreen revenues to an estimated $1.2M, which is within $300,000 of quarterly cash flow breakeven. The company's conversion rate data shows a high close rate once the sales team presents the product and its value proposition. Precipio's CEO, Ilan Danieli, stated that the company's HemeScreen product line stands above competition in terms of robustness, ease of use, and economics.
September 28, 2023 | 1:06 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Precipio's Q4 HemeScreen revenues are expected to reach $1.2M, nearing the cash flow breakeven point. The company's HemeScreen product line is performing well against competition.
The news is directly about Precipio and its HemeScreen product line. The expected increase in Q4 revenues and the positive performance of the HemeScreen product line against competition could potentially boost investor confidence and positively impact the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100